Health ❯ Healthcare ❯ Clinical Research

Drug Efficacy

Clinical Trials Weight Loss Medications Weight Loss Studies Side Effects Patient Outcomes Heart Health Ozempic and Alzheimer's Disease Lecanemab Statin Studies Antibiotic Use in STIs Amyloid-Aggregates Gender Differences Health Outcomes Antidepressant Studies Antibody Therapeutics Cognitive Decline PCSK9 Inhibitors Treatment Outcomes Weight Regain Tramadol Monoclonal Antibodies Beta-Blockers in Cardiac Patients Lenacapavir Studies Semaglutide Risk Assessment Tirzepatida Weight Loss Drugs Ivermectin and Cancer Cancer Therapies Antihistamines Pharmacokinetics Survival Rates

FDA Expands Mounjaro Label to Include Cardiovascular Risk Reduction

Regulators cited a head-to-head trial that showed about an 8% relative drop in major heart events versus Lilly’s older drug Trulicity, prompting wider use for high-risk adults with type 2 diabetes.

Immediate Evolocumab at PCI Cuts LDL but Fails to Lower One‑Year Events

HSE Drugs Group Recommends Against Funding Skyclarys as Final Vote Looms

Ivermectin Combo Prescriptions Jump After Mel Gibson Podcast, Study Finds

FDA Opens Safety Review of Infant RSV Antibody Drugs Beyfortus and Enflonsia

Real-World Study Finds Semaglutide and Tirzepatide Cut Cardiovascular Risk in Type 2 Diabetes

Major Review Finds Tramadol Delivers Minimal Chronic Pain Relief and Higher Serious Harm Risk

Trials Recast Post–Heart Attack Beta-Blocker Use, With Signal of Harm in Women